Literature DB >> 23540512

Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids.

Sebastiano Mercadante1, Giampiero Porzio, Federica Aielli, Claudio Adile, Lucilla Verna, Corrado Ficorella, Antonello Giarratano, Alessandra Casuccio.   

Abstract

OBJECTIVES: The aim of this exploratory study was to assess the conversion ratios between tapentadol and other opioids in patients requiring an opioid switching.
METHODS: A prospective study was carried out in a convenience sample of consecutive patients admitted to an acute palliative care unit and a home care unit for a period of 1 year. Patients who were switched from/to tapentadol were selected. The initial ratio between tapentadol and other opioids, expressed as oral morphine equivalents was 1:3.3. The subsequent doses were flexible and were changed to fit the patients' needs. Pain intensity and distress score were recorded until opioid doses were stable. In all, 37 patients were examined; 24 and 13 patients were switched from and to tapentadol, respectively.
RESULTS: The most frequent sequences were tapentadol-morphine (18 patients) in one direction, and morphine-tapentadol (8 patients) in the other direction. In the sequence tapentadol-morphine and morphine-tapentadol, the mean final tapentadol-morphine ratios were 3.9:1 (SD 2.3), and 1:4.5 (SD 3.2), respectively, which did not differ significantly from the initial established conversion ratio. A minority of patients were switched from/to tapentadol to/from other opioids. Globally, the initial ratio did not change after switching took place.
CONCLUSION: Data suggest that a conversion ratio between tapentadol and other opioids, expressed in oral morphine equivalents could be 1:3.3 in both direction, particularly in patients who are switched in conditions of equianalgesia. The limited number of patients prevents a definitive conclusion to be drawn, and data should be interpreted with caution, given the exploratory nature of the study and the question of the low number of patients should be addressed in future studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23540512     DOI: 10.1185/03007995.2013.791617

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  11 in total

1.  Opioid Rotation in Cancer Pain Treatment.

Authors:  Michael Schuster; Oliver Bayer; Florian Heid; Rita Laufenberg-Feldmann
Journal:  Dtsch Arztebl Int       Date:  2018-03-02       Impact factor: 5.594

2.  Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study.

Authors:  Jordi Barrachina; Cesar Margarit; Javier Muriel; Santiago López-Gil; Vicente López-Gil; Amaya Vara-González; Beatriz Planelles; María-Del-Mar Inda; Domingo Morales; Ana M Peiró
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

3.  Analysis of Various Factors Associated With Opioid Dose Escalation in Patients With Cancer Pain.

Authors:  Ryo Sakamoto; Atsuko Koyama
Journal:  Cureus       Date:  2022-05-24

4.  Impact of Perioperative Epidural Placement on Postdischarge Opioid Use in Patients Undergoing Abdominal Surgery.

Authors:  Karim S Ladha; Elisabetta Patorno; Jun Liu; Brian T Bateman
Journal:  Anesthesiology       Date:  2016-02       Impact factor: 7.892

5.  Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease.

Authors:  Flaminia Coluzzi; Robert B Raffa; Joseph Pergolizzi; Alessandra Rocco; Pamela Locarini; Natalia Cenfra; Giuseppe Cimino; Consalvo Mattia
Journal:  J Pain Res       Date:  2015-05-08       Impact factor: 3.133

6.  Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.

Authors:  Keiichiro Imanaka; Yushin Tominaga; Mila Etropolski; Hiroki Ohashi; Keiichiro Hirose; Taka Matsumura
Journal:  Clin Drug Investig       Date:  2014-07       Impact factor: 2.859

7.  Worldwide research productivity on tramadol: a bibliometric analysis.

Authors:  Waleed M Sweileh; Naser Y Shraim; Sa'ed H Zyoud; Samah W Al-Jabi
Journal:  Springerplus       Date:  2016-07-19

8.  Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study.

Authors:  M Cascella; C A Forte; S Bimonte; G Esposito; C Romano; R Costanzo; A Morabito; A Cuomo
Journal:  J Pain Res       Date:  2018-12-24       Impact factor: 3.133

Review 9.  Tapentadol in the management of cancer pain: current evidence and future perspectives.

Authors:  Hans G Kress; Flaminia Coluzzi
Journal:  J Pain Res       Date:  2019-05-16       Impact factor: 3.133

10.  Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study.

Authors:  Krista F Huybrechts; Brian T Bateman; Rishi J Desai; Sonia Hernandez-Diaz; Kathryn Rough; Helen Mogun; Leslie S Kerzner; Jonathan M Davis; Megan Stover; Devan Bartels; Jennifer Cottral; Elisabetta Patorno
Journal:  BMJ       Date:  2017-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.